How I treat AML relapse after allogeneic HSCT Available to Purchase

2.

Antin

J

.

Graft-versus-leukemia: no longer an epiphenomenon [editorial]

.

Blood

.

1993

;

82

(

8

):

2273

-

2277

.

3.

Barrett

AJ

,

Savani

BN

.

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

.

Leukemia

.

2006

;

20

(

10

):

1661

-

1672

.

4.

Horowitz

MM

,

Gale

RP

,

Sondel

PM

, et al.

Graft-versus-leukemia reactions after bone marrow transplantation

.

Blood

.

1990

;

75

(

3

):

555

-

562

.

5.

Valcárcel

D

,

Martino

R

,

Caballero

D

, et al.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival

.

J Clinc Oncol

.

2008

;

26

(

4

):

577

-

584

.

6.

Saad

A

,

Lamb

LS

.

Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future

.

Bone Marrow Transplant

.

2017

;

52

(

9

):

1241

-

1248

.

7.

Patriarca

F

,

Sperotto

A

,

Lorentino

F

, et al.

Donor lymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: a survey from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

.

Front Oncol

.

2020

;

10

:

572918

.

8.

Schmid

C

,

Labopin

M

,

Nagler

A

, et al;

Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation EBMT

.

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

.

Blood

.

2012

;

119

(

6

):

1599

-

1606

.

9.

Bejanyan

N

,

Weisdorf

DJ

,

Logan

BR

, et al.

Survival of AML patients relapsing after allogeneic hematopoietic cell transplantation: a CIBMTR study

.

Biol Blood Marrow Transplant

.

2015

;

21

(

3

):

454

-

459

.

10.

Cancer Genome Atlas Research Network

.

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

.

N Engl J Med

.

2013

;

368

(

22

):

2059

-

2074

.

11.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

12.

Lindsley

RC

,

Saber

W

,

Mar

BG

, et al.

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation

.

N Engl J Med

.

2017

;

376

(

6

):

536

-

547

.

13.

Daher-Reyes

G

,

Kim

T

,

Novitzky-Basso

I

, et al.

Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

.

Bone Marrow Transplant

.

2021

;

56

(

8

):

1908

-

1918

.

14.

Hourigan

CS

,

Gale

RP

,

Gormley

NJ

,

Ossenkoppele

GJ

,

Walter

RB

.

Measurable residual disease testing in acute myeloid leukaemia

.

Leukemia

.

2017

;

31

(

7

):

1482

-

1490

.

15.

Scott

BL

,

Pasquini

MC

,

Logan

BR

, et al.

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2017

;

35

(

11

):

1154

-

1161

.

16.

Scott

BL

,

Pasquini

MC

,

Fei

M

, et al.

Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes—long-term follow-up of the BMT CTN 0901 clinical trial

.

Transplant Cell Ther

.

2021

;

27

(

6

):

483.e1

-

483.e6

.

17.

Fasslrinner

F

,

Schetelig

J

,

Burchert

A

, et al.

Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

.

Lancet Haematol

.

2018

;

5

(

4

):

e161

-

e169

.

18.

Hourigan

CS

,

Dillon

LW

,

Gui

G

, et al.

Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease

.

J Clin Oncol

.

2020

;

38

(

12

):

1273

-

1283

.

19.

Barrett

AJ

.

Mechanisms of the graft-versus-leukemia reaction

.

Stem Cells

.

1997

;

15

(

4

):

248

-

258

.

20.

Sweeney

C

,

Vyas

P

.

The graft-versus-leukemia effect in AML

.

Front Oncol

.

2019

;

9

:

1217

.

21.

Granados

DP

,

Sriranganadane

D

,

Daouda

T

, et al.

Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides

.

Nat Commun

.

2014

;

5

:

3600

.

22.

van Els

CACM

,

D’Amaro

J

,

Pool

J

, et al.

Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance

.

Immunogenetics

.

1992

;

35

(

3

):

161

-

165

.

23.

den Haan

JMM

,

Sherman

NE

,

Blokland

E

, et al.

Identification of a graft versus host disease-associated human minor histocompatibility antigen

.

Science

.

1995

;

268

(

5216

):

1476

-

1480

.

24.

Greiner

J

,

Ono

Y

,

Hofmann

S

, et al.

Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia

.

Blood

.

2012

;

120

(

6

):

1282

-

1289

.

25.

Graf

C

,

Heidel

F

,

Tenzer

S

, et al.

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8⁺ T cells

.

Blood

.

2007

;

109

(

7

):

2985

-

2988

.

26.

Goswami

M

,

Hensel

N

,

Smith

BD

, et al.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues

.

Leukemia

.

2014

;

28

(

5

):

1167

-

1170

.

27.

Anguille

S

,

Van Tendeloo

VF

,

Berneman

ZN

.

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

.

Leukemia

.

2012

;

26

(

10

):

2186

-

2196

.

28.

Hadjis

AD

,

McCurdy

SR

.

The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation

.

Front Immunol

.

2024

;

15

:

1358668

.

29.

Ritz

J

.

Role of B cells in graft-versus-leukemia and graft-versus-host disease [abstract]

.

Blood

.

2013

;

122

(

21

):

SCI-3

.

30.

Christopher

MJ

,

Petti

AA

,

Rettig

MP

, et al.

Immune escape of relapsed AML cells after allogeneic transplantation

.

N Engl J Med

.

2018

;

379

(

24

):

2330

-

2341

.

31.

Vago

L

,

Perna

SK

,

Zanussi

M

, et al.

Loss of mismatched HLA in leukemia after stem-cell transplantation

.

N Engl J Med

.

2009

;

361

(

5

):

478

-

488

.

32.

Crucitti

L

,

Crocchiolo

R

,

Toffalori

C

, et al.

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

.

Leukemia

.

2015

;

29

(

5

):

1143

-

1152

.

33.

Toffalori

C

,

Zito

L

,

Gambacorta

V

, et al.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

.

Nat Med

.

2019

;

25

(

4

):

603

-

611

.

34.

Stone

RM

,

Mandrekar

SJ

,

Sanford

BL

, et al.

Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation

.

N Engl J Med

.

2017

;

377

(

5

):

454

-

464

.

35.

Jacoby

MA

,

Duncavage

EJ

,

Chang

GS

, et al.

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant

.

JCI Insight

.

2018

;

3

(

5

):

e98962

.

36.

Kekre

N

,

Kim

HT

,

Thanarajasingam

G

, et al.

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

.

Haematologica

.

2015

;

100

(

9

):

1222

-

1227

.

37.

Perl

AE

,

Martinelli

G

,

Cortes

JE

, et al.

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

.

N Engl J Med

.

2019

;

381

(

18

):

1728

-

1740

.

38.

Numan

Y

,

Abdel Rahman

Z

,

Grenet

J

, et al.

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors

.

Am J Hematol

.

2022

;

97

(

3

):

322

-

328

.

39.

Cortes

JE

,

Khaled

S

,

Martinelli

G

, et al.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

.

Lancet Oncol

.

2019

;

20

(

7

):

984

-

997

.

40.

Burchert

A

,

Bug

G

,

Fritz

LV

, et al.

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)

.

J Clin Oncol

.

2020

;

38

(

26

):

2993

-

3002

.

41.

Xuan

L

,

Wang

Y

,

Yang

K

, et al.

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

8

):

e600

-

e611

.

42.

Mathew

NR

,

Baumgartner

F

,

Braun

L

, et al.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

.

Nat Med

.

2018

;

24

(

3

):

282

-

291

.

43.

Levis

MJ

,

Hamadani

M

,

Logan

B

, et al;

BMT-CTN 1506/MORPHO Study Investigators

.

Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3

.

JCO

.

2024

;

42

(

15

):

1766

-

1775

.

44.

Karanes

C

,

Kopecky

KJ

,

Head

DR

, et al.

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study

.

Leuk Res

.

1999

;

23

(

9

):

787

-

794

.

45.

Greenberg

PL

,

Lee

SJ

,

Advani

R

, et al.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

.

J Clin Oncol

.

2004

;

22

(

6

):

1078

-

1086

.

46.

Russell

NH

,

Hills

RK

,

Kjeldsen

L

, et al.

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: results from the UK NCRI AML17 trial

.

Br J Haematol

.

2022

;

198

(

3

):

528

-

534

.

47.

Faderl

S

,

Wetzler

M

,

Rizzieri

D

, et al.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

.

J Clin Oncol

.

2012

;

30

(

20

):

2492

-

2499

.

48.

Cortes

JE

,

Goldberg

SL

,

Feldman

EJ

, et al.

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

.

Cancer

.

2015

;

121

(

2

):

234

-

242

.

49.

Konopleva

MY

,

Röllig

C

,

Cavenagh

J

, et al.

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

.

Blood Adv

.

2022

;

6

(

14

):

4147

-

4156

.

50.

Roboz

GJ

,

Sanz

G

,

Griffiths

EA

, et al.

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

.

Blood Adv

.

2024

;

8

(

8

):

2020

-

2029

.

51.

Roboz

GJ

,

Rosenblat

T

,

Arellano

M

, et al.

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

.

J Clin Oncol

.

2014

;

32

(

18

):

1919

-

1926

.

52.

Sievers

EL

,

Larson

RA

,

Stadtmauer

EA

, et al;

Mylotarg Study Group

.

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

.

J Clin Oncol

.

2001

;

19

(

13

):

3244

-

3254

.

53.

DiNardo

CD

,

Stein

EM

,

de Botton

S

, et al.

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

.

N Engl J Med

.

2018

;

378

(

25

):

2386

-

2398

.

54.

de Botton

S

,

Fenaux

P

,

Yee

K

, et al.

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

.

Blood Adv

.

2023

;

7

(

13

):

3117

-

3127

.

55.

de Botton

S

,

Montesinos

P

,

Schuh

AC

, et al.

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

.

Blood

.

2023

;

141

(

2

):

156

-

167

.

56.

Issa

GC

,

Aldoss

I

,

Thirman

MJ

, et al.

Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)

.

J Clin Oncol

.

2025

;

43

(

1

):

75

-

84

.

57.

Litzow

MR

,

Wang

XV

,

Carroll

MP

, et al.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

.

Am J Hematol

.

2019

;

94

(

1

):

111

-

117

.

58.

Short

NJ

,

Kantarjian

H

,

Ravandi

F

, et al.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

.

Leuk Lymphoma

.

2018

;

59

(

4

):

813

-

820

.

59.

Fiegl

M

,

Unterhalt

M

,

Kern

W

, et al;

German AML Cooperative Group AMLCG

.

Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG

.

Leukemia

.

2014

;

28

(

5

):

1001

-

1007

.

60.

Byrne

M

,

Danielson

N

,

Sengsayadeth

S

, et al.

The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia

.

Am J Hematol

.

2020

;

95

(

9

):

1006

-

1014

.

61.

Du

Y

,

Li

C

,

Zhao

Z

,

Liu

Y

,

Zhang

C

,

Yan

J

.

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis

.

BMC Cancer

.

2023

;

23

(

1

):

764

.

62.

Wille

K

,

Dumke

M

,

Wilsdorf

N

, et al.

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia

.

Eur J Haematol

.

2025

;

114

(

1

):

17

-

25

.

63.

Ruhnke

L

,

Schliemann

C

,

Mikesch

J-H

, et al.

Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage treatment for relapsed/refractory AML: updated results of the phase-I/II SAL relax trial [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

160

.

64.

Shimony

S

,

Bewersdorf

JP

,

Shallis

RM

, et al.

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

.

Leukemia

.

2024

;

38

(

4

):

762

-

768

.

65.

Alyea

EP

,

Soiffer

RJ

,

Canning

C

, et al.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant

.

Blood

.

1998

;

91

(

10

):

3671

-

3680

.

66.

Kolb

H

,

Mittermuller

J

,

Clemm

C

, et al.

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

.

Blood

.

1990

;

76

(

12

):

2462

-

2465

.

67.

Porter

DL

,

Roth

MS

,

McGarigle

C

,

Ferrara

J

,

Antin

JH

.

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

.

N Engl J Med

.

1994

;

330

(

2

):

100

-

106

.

68.

Schmid

C

,

Labopin

M

,

Nagler

A

, et al;

EBMT Acute Leukemia Working Party

.

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party

.

JCO

.

2007

;

25

(

31

):

4938

-

4945

.

69.

Bar

M

,

Sandmaier

BM

,

Inamoto

Y

, et al.

Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose

.

Biol Blood Marrow Transplant

.

2013

;

19

(

6

):

949

-

957

.

70.

Maurer

K

,

Antin

JH

.

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

.

Front Immunol

.

2024

;

15

:

1328858

.

71.

Claret

EJ

,

Alyea

EP

,

Orsini

E

, et al.

Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion

.

J Clin Invest

.

1997

;

100

(

4

):

855

-

866

.

72.

Bachireddy

P

,

Hainz

U

,

Rooney

M

, et al.

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion

.

Blood

.

2014

;

123

(

9

):

1412

-

1421

.

https://doi.org/10.1101/2024.02.09.579677

73.

Maurer

K

,

Park

CY

,

Mani

S

, et al.

Coordinated immune cell networks in the bone marrow microenvironment define the graft versus leukemia response with adoptive cellular therapy

.

bioRxiv

.

Preprint posted online 12 February 2024

.

74.

Kharfan-Dabaja

MA

,

Labopin

M

,

Polge

E

, et al.

Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse

.

JAMA Oncol

.

2018

;

4

(

9

):

1245

-

1253

.

75.

Shimoni

A

,

Labopin

M

,

Finke

J

, et al.

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

.

Blood Cancer J

.

2019

;

9

(

12

):

88

.

76.

Harris

AC

,

Mageneau

J

,

Braun

T

, et al.

Extramedullary relapse in acute leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes

.

Biol Blood Marrow Transplant

.

2010

;

16

(

2

):

S177

-

S178

.

77.

Shem-Tov

N

,

Saraceni

F

,

Danylesko

I

, et al.

Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse

.

Biol Blood Marrow Transplant

.

2017

;

23

(

7

):

1087

-

1094

.

78.

Penack

O

,

Abouqateb

M

,

Peczynski

C

, et al.

How risky is a second allogeneic stem cell transplantation?

.

Leukemia

.

2024

;

38

(

8

):

1799

-

1807

.

79.

Eapen

M

,

Giralt

SA

,

Horowitz

MM

, et al.

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

.

Bone Marrow Transplant

.

2004

;

34

(

8

):

721

-

727

.

80.

Hosing

C

,

Saliba

RM

,

Shahjahan

M

, et al.

Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia

.

Bone Marrow Transplant

.

2005

;

36

(

2

):

157

-

162

.

81.

Bosi

A

,

Laszlo

D

,

Labopin

M

, et al;

Acute Leukemia Working Party of the European Blood and Marrow Transplant Group

.

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation

.

J Clin Oncol

.

2001

;

19

(

16

):

3675

-

3684

.

82.

Schmälter

A-K

,

Ngoya

M

,

Galimard

J-E

, et al.

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

.

Blood Cancer J

.

2024

;

14

(

1

):

76

.

83.

Chong

G

,

Byrnes

G

,

Szer

J

,

Grigg

A

.

Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy

.

Bone Marrow Transplant

.

2000

;

26

(

9

):

1011

-

1015

.

84.

Shiravand

Y

,

Khodadadi

F

,

Kashani

SMA

, et al.

Immune checkpoint inhibitors in cancer therapy

.

Curr Oncol

.

2022

;

29

(

5

):

3044

-

3060

.

85.

Blazar

BR

,

Taylor

PA

,

Panoskaltsis-Mortari

A

,

Sharpe

AH

,

Vallera

DA

.

Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells

.

J Immunol

.

1999

;

162

(

11

):

6368

-

6377

.

86.

Davids

MS

,

Kim

HT

,

Bachireddy

P

, et al;

Leukemia and Lymphoma Society Blood Cancer Research Partnership

.

Ipilimumab for patients with relapse after allogeneic transplantation

.

N Engl J Med

.

2016

;

375

(

2

):

143

-

153

.

87.

Loke

J

,

McCarthy

N

,

Jackson

A

, et al.

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

.

Blood Adv

.

2023

;

7

(

14

):

3666

-

3676

.

88.

Murdock

HM

,

Ho

VT

,

Garcia

JS

.

Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect

.

Front Immunol

.

2024

;

15

:

1359113

.

89.

Garcia

JS

,

Kim

HT

,

Murdock

HM

, et al.

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

.

Blood Adv

.

2024

;

8

(

4

):

978

-

990

.

90.

Craddock

C

,

Jilani

N

,

Siddique

S

, et al.

Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial

.

Biol Blood Marrow Transplant

.

2016

;

22

(

2

):

385

-

390

.

91.

Heuser

M

,

Freeman

SD

,

Ossenkoppele

GJ

, et al.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

.

Blood

.

2021

;

138

(

26

):

2753

-

2767

.

92.

Platzbecker

U

,

Middeke

JM

,

Sockel

K

, et al.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

.

Lancet Oncol

.

2018

;

19

(

12

):

1668

-

1679

.

93.

Pagliuca

S

,

Schmid

C

,

Santoro

N

, et al;

Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation EBMT

.

Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT

.

Lancet Haematol

.

2024

;

11

(

6

):

e448

-

e458

.

94.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

95.

Short

NJ

,

Kantarjian

HM

,

Loghavi

S

, et al.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

.

Lancet Haematol

.

2019

;

6

(

1

):

e29

-

e37

.

96.

Pollyea

DA

,

Amaya

M

,

Strati

P

,

Konopleva

MY

.

Venetoclax for AML: changing the treatment paradigm

.

Blood Adv

.

2019

;

3

(

24

):

4326

-

4335

.

97.

DiNardo

CD

,

Maiti

A

,

Rausch

CR

, et al.

Ten-day decitabine with venetoclax in acute myeloid leukemia: a single-arm phase 2 trial

.

Lancet Haematol

.

2020

;

7

(

10

):

e724

-

e736

.

98.

DiNardo

CD

,

Tiong

IS

,

Quaglieri

A

, et al.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

.

Blood

.

2020

;

135

(

11

):

791

-

803

.

99.

Thol

F

,

Gabdoulline

R

,

Liebich

A

, et al.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

.

Blood

.

2018

;

132

(

16

):

1703

-

1713

.

100.

Dillon

LW

,

Gui

G

,

Page

KM

, et al.

DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant

.

JAMA

.

2023

;

329

(

9

):

745

-

755

.

101.

Murdock

HM

,

Kim

HT

,

Denlinger

N

, et al.

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

.

Blood

.

2022

;

139

(

24

):

3546

-

3557

.

102.

Letai

A

.

Precision medicine in AML: function plus -omics is better than either alone

.

Cancer Cell

.

2022

;

40

(

8

):

804

-

806

.

103.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

104.

Mishra

A

,

Tamari

R

,

DeZern

AE

, et al.

Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2022

;

40

(

34

):

3985

-

3993

.

105.

Uy

GL

,

Aldoss

I

,

Foster

MC

, et al.

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

.

Blood

.

2021

;

137

(

6

):

751

-

762

.

106.

Shapiro

RM

,

Birch

GC

,

Hu

G

, et al.

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse

.

J Clin Invest

.

2022

;

132

(

11

):

e154334

.

107.

Schroeder

T

,

Stelljes

M

,

Christopeit

M

, et al.

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-trial

.

Haematologica

.

2023

;

108

(

11

):

3001

-

3010

.

https://doi.org/10.1038/s41587-024-02348-3

108.

Cieri

N

,

Hookeri

N

,

Stromhaug

K

, et al.

Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation

.

Nat Biotechnol

.

Published online 21 August 2024

.

109.

Tambaro

FP

,

Singh

H

,

Jones

E

, et al.

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

.

Leukemia

.

2021

;

35

(

11

):

3282

-

3286

.

110.

Malki

MMA

,

Keyzner

A

,

Suh

HC

, et al.

TSC-100 and TSC-101, TCR-T cell therapies that target residual recipient cells after reduced intensity conditioning transplantation, induce complete donor chimerism with favorable prognosis: early results of a phase 1 trial

.

Transplant Cell Ther

.

2024

;

30

(

2

):

S1

-

S2

.